NEO2734
NEO2734 (EP31670) is an orally active dual p300/CBP and BET bromodomain selective inhibitor, with IC50 values of [1]. NEO2734 is active in SPOP mutant and wild-type prostate cancer[2].
Product Specifications
CAS Number
[2081072-29-7]
Product Name Alternative
EP31670
UNSPSC
12352005
Hazard Statement
H302, H312, H332
Target
Epigenetic Reader Domain; Histone Acetyltransferase
Type
Reference compound
Related Pathways
Epigenetics
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/neo2734.html
Purity
99.63
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C1C(C)=CC(C2=CC=C3N=C(C4CCOCC4)N(CCOC(F)(F)F)C3=C2)=CN1C
Molecular Formula
C22H24F3N3O3
Molecular Weight
435.44
Precautions
H302, H312, H332
References & Citations
[1]Chevaun D Morrison-Smit, et al. Combined Targeting of the BRD4-NUT-p300 Axis in NUT Midline Carcinoma by Dual Selective Bromodomain Inhibitor, NEO2734. Mol Cancer Ther. 2020 Jul;19 (7) :1406-1414.|[2]Yuqian Yan, et al. The novel BET-CBP/p300 dual inhibitor NEO2734 is active in SPOP mutant and wild-type prostate cancer. EMBO Mol Med. 2019 Nov 7;11 (11) :e10659.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 1
Isoform
CBP/p300
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
